Check-Cap (Check-Cap) 3-Year EPS without NRI Growth Rate : 54.10% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Check-Cap 3-Year EPS without NRI Growth Rate?

Check-Cap's EPS without NRI for the three months ended in Sep. 2023 was $-0.43.

During the past 3 years, the average EPS without NRI Growth Rate was 54.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 54.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Check-Cap was 59.50% per year. The lowest was -122.50% per year. And the median was 46.20% per year.

Competitive Comparison of Check-Cap's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Check-Cap's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Check-Cap's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Check-Cap's 3-Year EPS without NRI Growth Rate falls into.

Check-Cap 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Check-Cap (NAS:CHEK) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Check-Cap 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Check-Cap's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Check-Cap (Check-Cap) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

7CC:Germany

Address

29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000

Website

https://www.check-cap.com

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.